Results for "Bristol Myers Squibb"

The pharmaceutical company showcased long-term efficacy and safety results for mavacamten in treating obstructive hypertrophic cardiomyopathy at a major cardiology conference.

Pharmaceutical giant Bristol Myers Squibb has terminated its partnership agreement with cell therapy company Cellares regarding the development of a blood cancer treatment.

A potential $400 billion merger between pharmaceutical giants AstraZeneca and Bristol Myers Squibb, which would have marked a return to mega-deals in the pharma sector, ultimately fell apart.

Schrödinger projects a 10%-15% growth in its 2026 Annual Contract Value (ACV), coinciding with Bristol Myers Squibb's deployment of its Bunsen platform.

An analysis suggests that Bristol Myers Squibb stock may not be as undervalued as it appears, with one key factor identified that could potentially alter its valuation.

Bristol Myers Squibb has raised its full-year guidance after reporting stronger-than-expected second-quarter earnings, indicating a positive financial outlook.

An analysis compares Bristol Myers Squibb and Johnson & Johnson to determine which healthcare stock presents a better investment opportunity for 2026.

Bristol Myers Squibb has maintained an 18-year streak of dividend raises, with a specific indicator suggesting this trend will persist.

Bristol Myers Squibb announced that its multiple myeloma drug significantly improved patient survival by 50% in a late-stage clinical trial.

Investors are advised to watch four specific stocks, Bristol Myers Squibb (BMY), Lowe's (LOW), Nvidia (NVDA), and Intel (INTC), on Wednesday.

Bristol Myers Squibb and China's Hengrui Pharma have signed a licensing deal valued at up to $15.2 billion. This agreement involves a significant collaboration between the two pharmaceutical companies.

An analysis explores whether Bristol Myers Squibb represents the best value investment among major pharmaceutical companies. The article likely delves into the company's financials, pipeline, and market position.

An analysis explores whether investors should consider buying Bristol Myers Squibb stock, focusing on its 4.4%-yielding dividend.

Market opinion pieces argue that Bristol Myers Squibb remains a strong buy, though the underlying catalysts for the recommendation differ from typical pharmaceutical valuations.

Pharmaceutical giant Bristol Myers Squibb has terminated its development pact with cell therapy startup Cellares, forcing the smaller company to initiate a major corporate restructuring plan.

Rumors suggest British pharmaceutical giant AstraZeneca might pursue a merger with American competitor Bristol Myers Squibb, prompting commentary that such large-scale fusions often lead to failure.

AstraZeneca reportedly explored a potential acquisition of Bristol-Myers Squibb, a move that could have resulted in the largest pharmaceutical megadeal in history.

Bristol Myers Squibb's stock experienced a significant rise following reports of potential merger discussions with AstraZeneca.

Seeking Alpha analysts have released their latest recommendations, including upgrades and downgrades for prominent stocks such as Apple (AAPL), Carvana (CVNA), Bristol Myers Squibb (BMY), and Oracle (ORCL). This report provides insights into current market sentiment for these companies.

An analysis delves into the sustainability and attractiveness of Bristol Myers Squibb's dividend, questioning if its current yield is too good to be true for investors.

An article provides three reasons to consider buying stock in the pharmaceutical company Bristol Myers Squibb, offering investment insights.

Bristol Myers Squibb (BMS) held a press conference in Cyprus where medical oncologists highlighted the value of immuno-oncology and key factors for improving cancer patient care.

Pharmaceutical company Bristol Myers Squibb is investing millions in a new Swiss factory but will increasingly direct funds to the USA, compelled by US government protectionism to build a second factory there.

This week's notable healthcare headlines highlight developments concerning UnitedHealth, Bristol Myers Squibb, and Hims & Hers.

Jiangsu Hengrui Pharmaceutical, China's largest drug company, has entered into a global collaboration and licensing agreement with US pharmaceutical giant Bristol Myers Squibb (BMS) valued at up to US$15.2 billion.

The FDA has accepted Bristol Myers Squibb's New Drug Application (NDA) for Iberdomide, granting it Priority Review status. This indicates the agency's expedited review of the drug.

J&J has entered a strategic collaboration with biotech firm Sail Biomedicines to accelerate its chimeric antigen receptor T-cell development, aiming to outpace rival Bristol Myers Squibb in the immunotherapy space.

Major pharmaceutical companies Novartis, Eli Lilly, and Bristol Myers Squibb are reportedly showing interest in a clinical-stage cancer therapy, indicating potential future acquisitions or partnerships in the oncology space.

Reports of preliminary discussions between pharmaceutical giants AstraZeneca and Bristol Myers Squibb regarding a potential acquisition have been denied, clarifying earlier speculation over consolidation in the Big Pharma sector.

Talk of a potential megadeal between AstraZeneca and Bristol Myers Squibb (BMY) has created significant divisions and reactions in the market.

Bristol Myers Squibb (BMS) has been granted FDA review for a label expansion of its anemia therapy, developed in partnership with Merck.

An analysis compares Bristol Myers Squibb and Johnson & Johnson to determine which healthcare stock is a better investment buy for 2026.

An article provides an honest assessment of the safety and reliability of Bristol Myers Squibb's dividend, offering insights for investors.

Bristol Myers Squibb received first place for its Cancer Survivor Clinics at the EEFAM Excellence Awards. AbbVie also earned a Gold Excellence Award at the EEFAM 2026 for its Oncology Innovation.

An article provides insights and considerations for investors looking to purchase Bristol Myers Squibb stock, particularly when the share price is experiencing a dip.

U.S. drugmaker Bristol Myers Squibb inked a partnership with a Chinese company that some say could mark the next wave of collaboration across continents.

While American factories generally lag in adopting Artificial Intelligence, a Bristol Myers Squibb plant producing cancer drugs stands out as an exception. It was the sole U.S. manufacturer to be recognized for innovation by the World Economic Forum this year.

Analysts are recommending Bristol Myers Squibb (BMY) stock as a strong buy, forecasting a potential 16% upside for investors.

Bristol Myers Squibb's stock has experienced a 25% decline, prompting analysis on whether this presents a buying opportunity for investors.